Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaptAin
NCT06613516Phase 2Withdrawn
- Sponsor
- Imperial College London
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in breast cancer, sponsored by Imperial College London. Primary endpoints: Percentage of patients with complete ctDNA clearance at 2 years, Duration of ctDNA clearance at 2 years and 1 more. Planned start Feb 2025; status: withdrawn.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06613516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613516.